Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 23

1.

The pharmacokinetics and dosing of oral 4-methylumbelliferone for inhibition of hyaluronan synthesis in mice.

Kuipers HF, Nagy N, Ruppert SM, Sunkari VG, Marshall PL, Gebe JA, Ishak HD, Keswani SG, Bollyky J, Frymoyer AR, Wight TN, Steinman L, Bollyky PL.

Clin Exp Immunol. 2016 Sep;185(3):372-81. doi: 10.1111/cei.12815.

PMID:
27218304
2.

Opening clinical trial data: are the voluntary data-sharing portals enough?

Geifman N, Bollyky J, Bhattacharya S, Butte AJ.

BMC Med. 2015 Nov 11;13:280. doi: 10.1186/s12916-015-0525-y.

3.

Review of Environmental Impact on the Epigenetic Regulation of Atopic Diseases.

Sabounchi S, Bollyky J, Nadeau K.

Curr Allergy Asthma Rep. 2015 Jun;15(6):33. doi: 10.1007/s11882-015-0533-1. Review.

PMID:
26141578
4.

4-methylumbelliferone treatment and hyaluronan inhibition as a therapeutic strategy in inflammation, autoimmunity, and cancer.

Nagy N, Kuipers HF, Frymoyer AR, Ishak HD, Bollyky JB, Wight TN, Bollyky PL.

Front Immunol. 2015 Mar 23;6:123. doi: 10.3389/fimmu.2015.00123. Review.

5.

The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months.

Sosenko JM, Skyler JS, Beam CA, Boulware D, Mahon JL, Krischer JP, Greenbaum CJ, Rafkin LE, Matheson D, Herold KC, Palmer JP; Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups..

Diabetes Care. 2015 May;38(5):940-2. doi: 10.2337/dc14-2787.

6.

Heterogeneity in recent-onset type 1 diabetes - a clinical trial perspective.

Bollyky JB, Xu P, Butte AJ, Wilson DM, Beam CA, Greenbaum CJ; Type 1 Diabetes TrialNet Study Group..

Diabetes Metab Res Rev. 2015 Sep;31(6):588-94. doi: 10.1002/dmrr.2643.

7.

A new approach for diagnosing type 1 diabetes in autoantibody-positive individuals based on prediction and natural history.

Sosenko JM, Skyler JS, DiMeglio LA, Beam CA, Krischer JP, Greenbaum CJ, Boulware D, Rafkin LE, Matheson D, Herold KC, Mahon J, Palmer JP; Type 1 Diabetes TrialNet Study Group.; Diabetes Prevention Trial-Type 1 Study Group..

Diabetes Care. 2015 Feb;38(2):271-6. doi: 10.2337/dc14-1813.

8.

Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial.

Rigby MR, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Patel CM, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Moran A, Russell WE, Pinckney A, Keyes-Elstein L, Howell M, Aggarwal S, Lim N, Phippard D, Nepom GT, McNamara J, Ehlers MR; T1DAL Study Team..

Lancet Diabetes Endocrinol. 2013 Dec;1(4):284-94. doi: 10.1016/S2213-8587(13)70111-6.

9.

Acceleration of the loss of the first-phase insulin response during the progression to type 1 diabetes in diabetes prevention trial-type 1 participants.

Sosenko JM, Skyler JS, Beam CA, Krischer JP, Greenbaum CJ, Mahon J, Rafkin LE, Matheson D, Herold KC, Palmer JP; Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups..

Diabetes. 2013 Dec;62(12):4179-83. doi: 10.2337/db13-0656.

10.

Use of a "fuzzy logic" controller in a closed-loop artificial pancreas.

Mauseth R, Hirsch IB, Bollyky J, Kircher R, Matheson D, Sanda S, Greenbaum C.

Diabetes Technol Ther. 2013 Aug;15(8):628-33. doi: 10.1089/dia.2013.0036.

PMID:
23829285
11.

The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients.

Sosenko JM, Skyler JS, Palmer JP, Krischer JP, Yu L, Mahon J, Beam CA, Boulware DC, Rafkin L, Schatz D, Eisenbarth G; Type 1 Diabetes TrialNet Study Group.; Diabetes Prevention Trial-Type 1 Study Group..

Diabetes Care. 2013 Sep;36(9):2615-20. doi: 10.2337/dc13-0425.

12.

Evaluation of in vivo T cell kinetics: use of heavy isotope labelling in type 1 diabetes.

Bollyky JB, Long SA, Fitch M, Bollyky PL, Rieck M, Rogers R, Samuels PL, Sanda S, Buckner JH, Hellerstein MK, Greenbaum CJ.

Clin Exp Immunol. 2013 Jun;172(3):363-74. doi: 10.1111/cei.12064.

13.

Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials.

Moran A, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Greenbaum CJ, Herold KC, Marks JB, Raskin P, Sanda S, Schatz D, Wherrett DK, Wilson DM, Krischer JP, Skyler JS; Type 1 Diabetes TrialNet Canakinumab Study Group., Pickersgill L, de Koning E, Ziegler AG, Böehm B, Badenhoop K, Schloot N, Bak JF, Pozzilli P, Mauricio D, Donath MY, Castaño L, Wägner A, Lervang HH, Perrild H, Mandrup-Poulsen T; AIDA Study Group..

Lancet. 2013 Jun 1;381(9881):1905-15. doi: 10.1016/S0140-6736(13)60023-9.

14.

Reactivation of latent viruses in individuals receiving rituximab for new onset type 1 diabetes.

Kroll JL, Beam C, Li S, Viscidi R, Dighero B, Cho A, Boulware D, Pescovitz M, Weinberg A; Type 1 Diabetes TrialNet Anti CD-20 Study Group..

J Clin Virol. 2013 Jun;57(2):115-9. doi: 10.1016/j.jcv.2013.01.016.

15.

The role of hyaluronan and the extracellular matrix in islet inflammation and immune regulation.

Bollyky PL, Bogdani M, Bollyky JB, Hull RL, Wight TN.

Curr Diab Rep. 2012 Oct;12(5):471-80. doi: 10.1007/s11892-012-0297-0. Review.

16.

Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function.

Long SA, Rieck M, Sanda S, Bollyky JB, Samuels PL, Goland R, Ahmann A, Rabinovitch A, Aggarwal S, Phippard D, Turka LA, Ehlers MR, Bianchine PJ, Boyle KD, Adah SA, Bluestone JA, Buckner JH, Greenbaum CJ; Diabetes TrialNet and the Immune Tolerance Network..

Diabetes. 2012 Sep;61(9):2340-8. doi: 10.2337/db12-0049.

17.

Zinc transporter-8 autoantibodies improve prediction of type 1 diabetes in relatives positive for the standard biochemical autoantibodies.

Yu L, Boulware DC, Beam CA, Hutton JC, Wenzlau JM, Greenbaum CJ, Bingley PJ, Krischer JP, Sosenko JM, Skyler JS, Eisenbarth GS, Mahon JL; Type 1 Diabetes TrialNet Study Group..

Diabetes Care. 2012 Jun;35(6):1213-8. doi: 10.2337/dc11-2081.

18.

Effect of rituximab on human in vivo antibody immune responses.

Pescovitz MD, Torgerson TR, Ochs HD, Ocheltree E, McGee P, Krause-Steinrauf H, Lachin JM, Canniff J, Greenbaum C, Herold KC, Skyler JS, Weinberg A; Type 1 Diabetes TrialNet Study Group..

J Allergy Clin Immunol. 2011 Dec;128(6):1295-1302.e5. doi: 10.1016/j.jaci.2011.08.008.

19.

Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial.

Orban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Marks JB, Monzavi R, Moran A, Raskin P, Rodriguez H, Russell WE, Schatz D, Wherrett D, Wilson DM, Krischer JP, Skyler JS; Type 1 Diabetes TrialNet Abatacept Study Group..

Lancet. 2011 Jul 30;378(9789):412-9. doi: 10.1016/S0140-6736(11)60886-6.

20.

Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial.

Wherrett DK, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Herold KC, Marks JB, Monzavi R, Moran A, Orban T, Palmer JP, Raskin P, Rodriguez H, Schatz D, Wilson DM, Krischer JP, Skyler JS; Type 1 Diabetes TrialNet GAD Study Group..

Lancet. 2011 Jul 23;378(9788):319-27. doi: 10.1016/S0140-6736(11)60895-7.

Items per page

Supplemental Content

Loading ...
Support Center